Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Canakinumab es un anticuerpo monoclonal humano recombinante contra la interleucina-1β que se utiliza para el tratamiento de la artritis gotosa, la artritis juvenil y los síndromes de fiebre periódica. Administración subcutánea cada 4 a 12 semanas.
Its very high molecular weight explain the null or negligible passage to breast milk observed. (Weber 2022, Bosshard 2021)
No clinical problems or a higher rate of infections and no problems with routine vaccinations have been observed in infants of mothers receiving this drug. (Weber 2022, İlgen 2022, Bosshard 2021, Youngstein 2017)
Due to its protein nature, it is inactivated in the gastrointestinal tract, not being absorbed (practically nil oral bioavailability), which hinders or prevents the passage into plasma of the infant from ingested breast milk (Lactmed), except in premature infants and during the immediate neonatal period, in which there may be greater intestinal absorption.